Withdrawal of anticancer therapy in advanced disease: a systematic literature review
Conclusions:
Oncologists report that decisions around stopping chemotherapy treatment are challenging, with limited evidence-based guidance outside of clinical trial protocols. The increasing availability of oral MTAs is transforming the management of incurable cancer; blurring boundaries between active treatment and palliative care. No studies specifically addressing decision-making around stopping MTAs in clinical practice were identified. There is a need to develop an evidence base to support physicians and patients with decision-making around the withdrawal of these high cost treatments.
Source: BMC Cancer - Category: Cancer & Oncology Authors: G. ClarkeS. JohnstonP. CorrieI. KuhnS. Barclay Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Databases & Libraries | Medical Training Application Service | Oral Cancer | Palliative | Palliative Care | Study | Toxicology